Zobrazeno 1 - 10
of 3 399
pro vyhledávání: '"opioid agonist"'
Publikováno v:
BMC Psychiatry, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Opioid agonist treatment (OAT) is the preferred treatment for opioid dependence due to benefits such as treatment retention, reduced opioid use and mortality. Benzodiazepine co-dependence is common in OAT patients and has been lin
Externí odkaz:
https://doaj.org/article/4ed86ee8cb8148c595cf083e7105a65b
Autor:
Raminta Stuikyte, Ivan Varentsov, Naimdzhon Malikov, Sergii Dvoriak, Myroslava Filippovych, Alisher Latypov, Aleksei Kralko, Ala Iatco, Catherine Cook
Publikováno v:
Harm Reduction Journal, Vol 21, Iss 1, Pp 1-17 (2024)
Abstract Background Most national programmes of opioid agonist therapy (OAT) in Eastern Europe and Central Asia are at a critical juncture for building their sustainability due to decreasing support from the Global Fund and other international HIV fu
Externí odkaz:
https://doaj.org/article/6366695e64ed45a999fcec923690019f
Publikováno v:
Harm Reduction Journal, Vol 21, Iss 1, Pp 1-10 (2024)
Abstract Background Understanding the heterogeneity of opioid overdose fatalities is critical to developing effective preventive interventions. This study examines patterns of care contacts among people who subsequently died from opioid overdose. The
Externí odkaz:
https://doaj.org/article/faa7da01836e40a6bbf88500c7b8bf05
Autor:
Mélanie Pinhal, Benoit Schreck, Juliette Leboucher, STIGMA-group, Caroline Victorri-Vigneau, Edouard-Jules Laforgue, Marie Grall-Bronnec
Publikováno v:
Addiction Science & Clinical Practice, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background In the context of the opioid overdose crisis, understanding the barriers to seeking, attaining and remaining in treatment for patients with opioid use disorder (OUD) is a public health issue. To date, very few studies have assesse
Externí odkaz:
https://doaj.org/article/1b5e34be166f4352906bb668f6e86cf3
Autor:
Brendan Kahn, Michel Kazatchkine
Publikováno v:
Harm Reduction Journal, Vol 21, Iss 1, Pp 1-4 (2024)
Abstract Europe has been at the forefront of harm reduction since its inception. These important early steps were in large part a response to the dramatically expanding HIV epidemic, and investing in these innovative interventions early and robustly
Externí odkaz:
https://doaj.org/article/990e232477364a94b8b24ff54e6f8312
Autor:
Webster, Russell, Fearns, Colin, Harriott, Paula, Millar, Lisa, Simpson, Jardine, Wallace, Jason, Wheatley, Michael
Publikováno v:
International Journal of Prison Health, 2023, Vol. 20, Issue 2, pp. 143-155.
Externí odkaz:
http://www.emeraldinsight.com/doi/10.1108/IJOPH-05-2023-0025
Autor:
John Todd-Kvam, Thomas Clausen
Publikováno v:
Addiction Science & Clinical Practice, Vol 19, Iss 1, Pp 1-14 (2024)
Abstract Background Norway has a growing proportion of ageing opioid agonist treatment (OAT) patients, with 42% of the 8300 Norwegian OAT patients aged over 50 in 2022. This study aims to explore practitioners’ views and experiences from treatment
Externí odkaz:
https://doaj.org/article/68b39e4695d84e7aa2ffbe1229000aa6
Publikováno v:
Addiction Science & Clinical Practice, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background Knowledge of co-occurring mental disorders (termed ‘dual diagnosis’) among patients receiving opioid agonist treatment (OAT) is scarce. This study aimed (1) to estimate the prevalence and structure of dual diagnoses in two nat
Externí odkaz:
https://doaj.org/article/310d9b23dc4341008ae3f87572077137
Autor:
Eshan U. Patel, Suzanne M. Grieb, Abigail K. Winiker, Jennifer Ching, Catherine G. Schluth, Shruti H. Mehta, Gregory D. Kirk, Becky L. Genberg
Publikováno v:
Harm Reduction Journal, Vol 21, Iss 1, Pp 1-17 (2024)
Abstract Background Substance use disorder treatment and recovery support services are critical for achieving and maintaining recovery. There are limited data on how structural and social changes due to the COVID-19 pandemic impacted individual-level
Externí odkaz:
https://doaj.org/article/10846a498b2744dbbc1260df5d1836b6
Autor:
Benjamin L. H. Jones, Michelle Geier, John Neuhaus, Phillip O. Coffin, Hannah R. Snyder, Christine S. Soran, Kelly R. Knight, Leslie W. Suen
Publikováno v:
Harm Reduction Journal, Vol 21, Iss 1, Pp 1-8 (2024)
Abstract Background Buprenorphine is an effective treatment for opioid use disorder (OUD); however, buprenorphine initiation can be complicated by withdrawal symptoms including precipitated withdrawal. There has been increasing interest in using low
Externí odkaz:
https://doaj.org/article/b4c41ab2d7a449558a7b815bf179adac